Mirum Pharmaceuticals, Inc.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $521.3M
- Net income
- -$23.4M
- Total assets
- $842.8M
- Market cap
- $5.7B
- Operating margin
- -4.2%
- Net margin
- -4.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $521.3M
- Operating expenses
- $543.4M
- Operating income
- -$22.1M
- Income tax
- $1.9M
- Net income
- -$23.4M
- EPS (basic)
- $-0.47
- EPS (diluted)
- $-0.47
Balance sheet
- Total assets
- $842.8M
- Current assets
- $549.7M
- Total liabilities
- $528.1M
- Current liabilities
- $205.8M
- Shareholders’ equity
- $314.7M
Cash flow
- Operating cash flow
- $55.8M
- Investing cash flow
- -$24.0M
- Financing cash flow
- $40.1M
- Net cash flow
- $72.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.7B
- EPS (diluted)
- $-0.47
- Shares outstanding
- 60.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 18, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $23.4M in FY2025.
- Revenue grew 2624% from FY2021 to FY2025.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Mirum Pharmaceuticals, Inc..
Write a review
News about Mirum Pharmaceuticals, Inc.
News & sentiment via Polygon.io
